Efficacy and safety of TAS-102 plus Surufatinib in third and later line metastatic pancreatic cancer: a prospective, single center and biomarker exploratory, phase II study.
Saved in:
| Title: | Efficacy and safety of TAS-102 plus Surufatinib in third and later line metastatic pancreatic cancer: a prospective, single center and biomarker exploratory, phase II study. |
|---|---|
| Authors: | Lu, Yunxin1,2 (AUTHOR) luyx@sysucc.org.cn, Lin, Qingguang2,3 (AUTHOR) linqg@sysucc.org.cn, Mo, Yongxin1,2 (AUTHOR) moyx2@sysucc.org.cn, Liu, Furong2,4 (AUTHOR) liufr@sysucc.org.cn, Zhang, Mengwei1,2 (AUTHOR) zhangmw@sysucc.org.cn, Huang, Runjie1,2 (AUTHOR) huangrj@sysucc.org.cn, Wang, Yun1,2 (AUTHOR) wangyun1@sysucc.org.cn, Wang, Yinnan1,2 (AUTHOR) wangyn@sysucc.org.cn, Wang, Zhiqiang1,2 (AUTHOR) wangzhq@sysucc.org.cn, Luo, Huiyan1,2 (AUTHOR) luohy@sysucc.org.cn, Guo, Guifang2,5 (AUTHOR) guogf@sysucc.org.cn, Chen, Jianwen1,2 (AUTHOR) chenjianw@sysucc.org.cn, Liu, Yu2,4 (AUTHOR) liuyu@sysucc.org.cn, He, Mingming1,2 (AUTHOR) hemm@sysucc.org.cn, Wang, Fenghua1,2 (AUTHOR) wangfh@sysucc.org.cn, Wang, Feng1,2 (AUTHOR) wangfeng@sysucc.org.cn, Zhang, Dongsheng1,2 (AUTHOR) zhangdsh@sysucc.org.cn |
| Source: | Molecular Cancer. 10/2/2025, Vol. 24 Issue 1, p1-17. 17p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 14764598 |
|---|---|
| DOI: | 10.1186/s12943-025-02437-0 |
